Publicaciones científicas

Adverse Skin Effects of Imatinib, a Tyrosine Kinase Inhibitor

Pretel-Irazabal M (1), Tuneu-Valls A (2), Ormaechea-Pérez N (2).
(1) Departamento de Dermatología, Clínica Universidad de Navarra, Pamplona, España.
(2) Departamento de Dermatología, Hospital de Donostia, San Sebastián, España. 

Magazine: Actas Dermo-Sifiliográficas

Date: Sep 1, 2014

Dermatology

ABSTRACT

Imatinib mesylate is a tyrosine kinase inhibitor that targets the BCR-ABL, c-kit, and PDGF (platelet-derived growth factor) receptors.

Imatinib is mainly indicated for chronic myeloid leukemia and gastrointestinal stromal tumors but is also prescribed by dermatologists for dermatofibrosarcoma protuberans, systemic sclerosis, and systemic mastocytosis, among other conditions. Most adverse effects are mild or moderate and therapy is generally well tolerated.

Adverse skin effects are very common and include nonspecific manifestations such as edema and maculopapular rashes or eruptions of diverse types (lichenoid or psoriasiform lesions, acute generalized exanthematic pustulosis, Stevens-Johnson syndrome, and more).

Identifying and properly treating these reactions can help optimize adherence to treatment and improve the prognosis of the underlying disease.

CITATION  Actas Dermosifiliogr. 2014 Sep;105(7):655-62. doi: 10.1016/j.ad.2013.01.009. Epub 2013 Apr 30

tal vezLE INTERESE

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra